Scientific Reports (Jul 2021)
Impact of modified albumin–bilirubin grade on survival in patients with HCC who received lenvatinib
- Toshifumi Tada,
- Takashi Kumada,
- Atsushi Hiraoka,
- Masanori Atsukawa,
- Masashi Hirooka,
- Kunihiko Tsuji,
- Toru Ishikawa,
- Koichi Takaguchi,
- Kazuya Kariyama,
- Ei Itobayashi,
- Kazuto Tajiri,
- Noritomo Shimada,
- Hiroshi Shibata,
- Hironori Ochi,
- Satoshi Yasuda,
- Hidenori Toyoda,
- Shinya Fukunishi,
- Hideko Ohama,
- Kazuhito Kawata,
- Joji Tani,
- Shinichiro Nakamura,
- Kazuhiro Nouso,
- Akemi Tsutsui,
- Takuya Nagano,
- Tanaka Takaaki,
- Norio Itokawa,
- Tomomi Okubo,
- Taeang Arai,
- Michitaka Imai,
- Kouji Joko,
- Yohei Koizumi,
- Yoichi Hiasa,
- Real-life Practice Experts for HCC (RELPEC) Study Group and the HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
Affiliations
- Toshifumi Tada
- Department of Internal Medicine, Japanese Red Cross Himeji Hospital
- Takashi Kumada
- Faculty of Nursing, Gifu Kyoritsu University
- Atsushi Hiraoka
- Gastroenterology Center, Ehime Prefectural Central Hospital
- Masanori Atsukawa
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School
- Masashi Hirooka
- Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine
- Kunihiko Tsuji
- Center of Gastroenterology, Teine Keijinkai Hospital
- Toru Ishikawa
- Department of Gastroenterology, Saiseikai Niigata Hospital
- Koichi Takaguchi
- Department of Hepatology, Kagawa Prefectural Central Hospital
- Kazuya Kariyama
- Department of Gastroenterology, Okayama City Hospital
- Ei Itobayashi
- Department of Gastroenterology, Asahi General Hospital
- Kazuto Tajiri
- Department of Gastroenterology, Toyama University Hospital
- Noritomo Shimada
- Division of Gastroenterology and Hepatology, Otakanomori Hospital
- Hiroshi Shibata
- Department of Gastroenterology, Tokushima Prefectural Central Hospital
- Hironori Ochi
- Hepato-Biliary Center, Matsuyama Red Cross Hospital
- Satoshi Yasuda
- Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital
- Hidenori Toyoda
- Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital
- Shinya Fukunishi
- Second Department of Internal Medicine, Osaka Medical College
- Hideko Ohama
- Second Department of Internal Medicine, Osaka Medical College
- Kazuhito Kawata
- Hepatology Division, Department of Internal Medicine, Hamamatsu University School of Medicine
- Joji Tani
- Department of Gastroenterology and Neurology, Kagawa University School of Medicine
- Shinichiro Nakamura
- Department of Internal Medicine, Japanese Red Cross Himeji Hospital
- Kazuhiro Nouso
- Department of Gastroenterology, Okayama City Hospital
- Akemi Tsutsui
- Department of Hepatology, Kagawa Prefectural Central Hospital
- Takuya Nagano
- Department of Hepatology, Kagawa Prefectural Central Hospital
- Tanaka Takaaki
- Gastroenterology Center, Ehime Prefectural Central Hospital
- Norio Itokawa
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School
- Tomomi Okubo
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School
- Taeang Arai
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School
- Michitaka Imai
- Department of Gastroenterology, Saiseikai Niigata Hospital
- Kouji Joko
- Hepato-Biliary Center, Matsuyama Red Cross Hospital
- Yohei Koizumi
- Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine
- Yoichi Hiasa
- Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine
- Real-life Practice Experts for HCC (RELPEC) Study Group and the HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
- DOI
- https://doi.org/10.1038/s41598-021-93794-5
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 11
Abstract
Abstract We investigated the impact on survival of modified albumin–bilirubin (mALBI) grade versus Child–Pugh classification in patients with hepatocellular carcinoma (HCC) who received lenvatinib. A total of 524 patients with HCC who received lenvatinib were included. Univariate analysis showed that mALBI grade 2b/3 and Child–Pugh class B/C were significantly associated with survival [hazard ratio (HR), 2.471; 95% confidence interval (CI), 1.944–3.141 and HR, 2.178; 95%CI, 1.591–2.982]. In patients with a Child–Pugh score of 5, multivariate analysis showed that mALBI grade 2b/3 was independently associated with survival (HR, 1.814; 95%CI, 1.083–3.037). Conversely, among patients with mALBI grade 1/2a, there was no difference in survival between those with a Child–Pugh class of 5 or 6 (p = 0.735). Time-dependent receiver operating characteristic analysis showed that the ALBI score predicted survival better than the Child–Pugh score. The optimal cut-off value of the ALBI score for predicting survival was nearly the same as the value separating mALBI grades 2a and 2b. In conclusion, the mALBI grade was a better predictor of survival than the Child–Pugh classification in patients with unresectable HCC who received lenvatinib therapy.
